MorphoSys AG
MorphoSys AG, located in Martinsried/Munich, is one of the world's leading biotechnology companies focusing on fully human antibodies. With its unique technologies , MorphoSys is developing the next generation of therapeutic antibodies, which can be used not only for research and diagnostics but also to treat diseases. Numerous partnerships have already been entered into with well-known companies from the pharmaceutical and biotechnology sectors, such as Schering, Bayer, Centocor/Johnson & Johnson and Roche.
The company, founded in 1992, possesses the unique HuCAL® technology (the Human Combinatorial Antibody Library). This library comprises more than ten billion different, fully human antibodies. HuCAL® is a very powerful technology, which allows rapid and automated production of high-affinity antibodies. The most important feature of the library is its capability of optimizing fully human antibodies to meet pre-defined specifications.
MorphoSys has been successful in establishing a number of partnerships with renowned biotechnology and pharmaceutical companies as a means of validating and commercializing its technologies. More recently, the company has changed its business model from a technology company provider to a product development company . The new business model comprises both commercialization of the HuCAL® technology and building a pipeline with own antibody products. With regard to its own proprietary products, MorphoSys intends to focus on indications of inflammation, cancer and infectious diseases. The aim of MorphoSys is to continuously enhance the value of the company by in-house drug development – thus tapping into the full potential of the unique proprietary technology.
MorphoSys AG, located in Martinsried/Munich, is one of the world's leading biotechnology companies focusing on fully human antibodies. With its unique technologies , MorphoSys is developing the next generation of therapeutic antibodies, which can be used not only for research and diagnostics but also to treat diseases. Numerous partnerships have already been entered into with well-known companies from the pharmaceutical and biotechnology sectors, such as Schering, Bayer, Centocor/Johnson & Johnson and Roche.
The company, founded in 1992, possesses the unique HuCAL® technology (the Human Combinatorial Antibody Library). This library comprises more than ten billion different, fully human antibodies. HuCAL® is a very powerful technology, which allows rapid and automated production of high-affinity antibodies. The most important feature of the library is its capability of optimizing fully human antibodies to meet pre-defined specifications.
MorphoSys has been successful in establishing a number of partnerships with renowned biotechnology and pharmaceutical companies as a means of validating and commercializing its technologies. More recently, the company has changed its business model from a technology company provider to a product development company . The new business model comprises both commercialization of the HuCAL® technology and building a pipeline with own antibody products. With regard to its own proprietary products, MorphoSys intends to focus on indications of inflammation, cancer and infectious diseases. The aim of MorphoSys is to continuously enhance the value of the company by in-house drug development – thus tapping into the full potential of the unique proprietary technology.